Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 778Lymphoid 33Gynecologic 23Thoracic 20Head & Neck 17Tumor-Agnostic 16Breast 15Genitourinary 13Other solid neoplasm 10Other hematologic neoplasm 5CNS 4Sarcoma 2Endocrine 2Other neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oxaliplatin × NET × Clear all
NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡